Phase II trial of surufatinib plus toripalimab for disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junction adenocarcinoma.

Lin Shen,Ming Lu,Zhendong Chen,Feng Ye,Yanqiao Zhang,Zhiping Li,Xing Zhang,Fei Yin,Wei Chen,Wang Sheng,Yue Ma,Yaqin Zhao,De Sheng Weng,Xiaolei Yin,Jinghong Zhou,Haiyan Shi,Panfeng Tan,Weiguo Su

Phase II trial of surufatinib plus toripalimab for disease progression after first-line chemotherapy with platinum and fluoropyrimidine in advanced gastric or gastroesophageal junction adenocarcinoma.

2021

Lin Shen
Ming Lu
Zhendong Chen
Feng Ye
Yanqiao Zhang
Zhiping Li
Xing Zhang
Fei Yin
Wei Chen
Wang Sheng
Yue Ma
Yaqin Zhao
De Sheng Weng
Xiaolei Yin
Jinghong Zhou
Haiyan Shi
Panfeng Tan
Weiguo Su

e16040Background: Surufatinib is a novel small-molecule kinase inhibitor targeting VEGFRs, FGFR and CSF-1R, simultaneous targeting of angiogenesis through VEGFRs/FGFR1 and modulating tumor immune m...

Keywords:

Cancer research
Kinase
Immune system
Medicine
Angiogenesis
first line chemotherapy
disease progression
Gastroesophageal Junction Adenocarcinoma
Fibroblast growth factor receptor 1
Fibroblast growth factor receptor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations